https://pepsreview.com/articles/novo-nordisk-customers-live-lighter-fda-ad-enforcement PepsReview en 2026-10-12 Novo Nordisk, Wegovy, FDA untitled letter, GLP-1 advertising, direct-to-consumer ads, live lighter, drug marketing enforcement https://pepsreview.com/articles/us-glp-1-labels-still-lack-naion-warning-fda-review-pending PepsReview en 2026-10-12 NAION, GLP-1 vision loss, FDA label warning, Ozempic, Mounjaro, semaglutide, EMA safety review, drug labeling https://pepsreview.com/articles/fda-503b-bulks-list-exclusion-glp-1-decision-pending PepsReview en 2026-10-11 FDA 503B bulks list, semaglutide compounding, tirzepatide, liraglutide, GLP-1 regulation, compounded GLP-1, peptide regulation https://pepsreview.com/articles/lillys-foundayo-six-months-first-non-peptide-glp-1-pill PepsReview en 2026-10-11 Foundayo, orforglipron, Eli Lilly, GLP-1 pill, oral GLP-1, non-peptide agonist, weight loss drug, FDA approval https://pepsreview.com/articles/novo-nordisk-amycretin-phase-2-diabetes-weight-loss PepsReview en 2026-10-11 amycretin, zenagamtide, Novo Nordisk, GLP-1, amylin, type 2 diabetes, weight loss drug, clinical trial https://pepsreview.com/articles/glp-1-injury-claims-data-gap-courts-regulators PepsReview en 2026-10-10 GLP-1 lawsuits, Ozempic litigation, NAION, semaglutide safety, tirzepatide, adverse event reporting, pancreatitis, FDA